Strategies to overcome biological barriers to biosensing

Chemical Analysis

Volumn 174, Issue , 2010, Pages 59-86

  Ward, W Kenneth ^a   Duman, Heather M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862110495     PISSN: 00692883     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (126)

1. Tang L, Eaton JW. Fibrin(ogen) mediates acute inflammatory responses to biomaterials. Journal of Experimental Medicine 1993, 178, 2147-2156. (Pubitemid 23344872)
2. Tang L, Ugarova TP, Plow EF, Eaton JW. Molecular determinants of acute inflammatory responses to biomaterials. Journal of Clinical Investigation 1996, 97, 1329-1334. (Pubitemid 26085490)
3. Tang L, Wu Y, Timmons RB. Fibrinogen adsorption and host tissue responses to plasma functionalized surfaces. Journal of Biomedical Materials Research 1998, 42, 156-163. (Pubitemid 28413008)
4. Ward WK, Wood MD, Casey HM, Quinn MJ, Federiuk IF. An implantable subcutaneous glucose sensor array in ketosis-prone rats: closed loop glycemic control. Artificial Organs 2005, 29, 131-143. (Pubitemid 41623718)
5. Zdolsek J, Eaton JW, Tang L. Histamine release and fibrinogen adsorption mediate acute inflammatory responses to biomaterial implants in humans. Journal of Translational Medicine 2007, 5, 31.
6. Tang L, Jennings TA, Eaton JW. Mast cells mediate acute inflammatory responses to implanted biomaterials. Proceedings of the National Academy of Sciences of the United States of America 1998, 95, 8841-8846. (Pubitemid 28350576)
7. Greenhalgh D. The role of monocytes/macrophages in wound healing. In: Robinson JP, Babcock GF (Eds), Phagocyte Function: A Guide for Research and Clinical Evaluation. Wiley-Liss Inc., 1998, pp. 349-357.
8. Kao WJ, McNally AK, Hiltner A, Anderson JM. Role for interleukin-4 in foreign-body giant cell formation on a poly(etherurethane urea) in vivo. Journal of Biomedical Materials Research 1995, 29, 1267-1275.
9. Tsai AT, Rice J, Scatena M, Liaw L, Ratner BD, Giachelli CM. The role of osteopontin in foreign body giant cell formation. Biomaterials 2005, 26, 5835-5843. (Pubitemid 40803458)
10. El-Warrak AO, Olmstead M, Apelt D, Deiss F, Noetzli H, Zlinsky K, Hilbe M, Bertschar-Wolfsberger R, Johnson AL, Auer J, von Rechenberg B. An animal model for interface tissue formation in cemented hip replacements. Veterinary Surgery 2004, 33, 495-504. (Pubitemid 41742806)
11. Wozniak W, Markuszewski J, Wierusz-Kozlowska M, Wysocki H. Neutrophils are active in total joint implant loosening. Acta Orthopaedica Scandinavica 2004, 75, 549-553. (Pubitemid 39425277)
12. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. Journal of Biomedical Materials Research 1997, 37, 401-412. (Pubitemid 27481455)
13. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. Journal of Biomedical Materials Research 1998, 40, 586-597. (Pubitemid 28225844)
14. Wisniewski N, Moussy F, Reichert WM. Characterization of implantable biosensor membrane biofouling. Fresenius Journal of Analytical Chemistry 2000, 366, 611-621.
15. Wisniewski N, Reichert M. Methods for reducing biosensor membrane biofouling. Colloids and Surfaces B. Biointerfaces 2000, 18, 197-219. (Pubitemid 30479863)
16. LiAG, Quinn MJ, SiddiquiY,Wood MD, Federiuk IF, Duman HM, Ward WK. Elevation of transforming growth factor beta (TGFbeta) and its downstream mediators in subcutaneous foreignbodycapsule tissue. JournalofBiomedicalMaterialsResearchA82,2007,498-508. (Pubitemid 47051682)
17. Ward WK,LiAG, SiddiquiY,Federiuk IF,Wang X-J. Increased expressionofinterleukin-13 and connective tissue growth factor, and their potential roles during foreign body encapsulation of subcutaneous implants. Journal of Biomaterials Science, Polymer Edition 2008, 19, 1065-1072. (Pubitemid 351957391)
18. Border WA. Transforming growth factor-b and the pathogenesis of glomerular diseases. Current Opinion in Nephrology and Hypertension 1994, 3, 54-58.
19. Chen K, Wei Y, Sharp GC, Braley-Mullen H. Inhibition of TGFb1 by anti-TGFb1 antibody or lisinopril reduces thyroid fibrosis in granulomatous experimental autoimmune thyroiditis. Journal of Immunology 2002, 169, 6530-6538. (Pubitemid 36903505)
20. Atamas SP, White B.The roleofchemokines in the pathogenesis of scleroderma. Current Opinion in Rheumatology 2003, 15, 772-777.
21. Leask A, Abraham DJ. TGF-b signaling and the fibrotic response. Journal of the Federation of American Societies for Experimental Biology 2004, 18, 816-827.
22. Parekh T, Saxena B, Reibman J, Cronstein BN, Gold LI. Neutrophil chemotaxis in response to TGF-b isoforms (TGF-b1, TGF-b2, TGF-b3) is mediated by fibronectin. Journal of Immunology 1994, 152, 2456-2466. (Pubitemid 24097938)
23. Brodbeck WG, Voskerician G, Ziats NP, Nakayama Y, Matsuda T, Anderson JM. In vivo leukocyte cytokine mRNA responses to biomaterials are dependent on surface chemistry. Journal of Biomedical Materials Research A 2003, 64, 320-329. (Pubitemid 37521452)
24. Robitaille R, Dusseault J, Henley N, Desbiens K, Labrecque N, Halle J-P. Inflammatory response to peritoneal implantation of alginate-poly-L-lysine microcapsules. Biomaterials 2005, 26, 4119-4127. (Pubitemid 40138658)
25. O'Kane S, Ferguson MW. Transforming growth factor-bs and wound healing. International Journal of Biochemistry and Cell Biology 1997, 29, 63-78. (Pubitemid 27096420)
26. McCormickLL, ZhangY,TootellE,GilliamAC. Anti-TGF-btreatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. Journal of Immunology 1999, 163, 5693-5699.
27. Hetzel GR, Hermsen D, Hohlfeld T, Rettich A, Ozcan F, Fussholler A, Grabensee B, Plum J. Effects of candesartan and perindopril on renal function, TGF-b1 plasma levels and excretion of prostaglandins in stable renal allograft recipients. Clinical Nephrology 2002, 57, 296-302. (Pubitemid 34296391)
28. Oriente A, Fedarko NS, Pacocha SE, Huang S-K, Lichtenstein LM, Essayan DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. Journal of Pharmacology and Experimental Therapeutics 2000, 292, 988-994. (Pubitemid 30136592)
29. Jinnin M, Ihn H, Yamane K, Tamaki K. Interleukin-13 stimulates the transcription of the human a2(I) collagen gene in human dermal fibroblasts. Journal of Biological Chemistry 2004, 279, 41783-41791. (Pubitemid 39313625)
30. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitamins and Hormones 2006, 74, 479-504.
31. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor-b1. Journal of Experimental Medicine 2001, 194, 809-821. (Pubitemid 32983016)
32. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13a2 receptor is involved in induction of TGF-b1 production and fibrosis. Nature Medicine 2006, 12, 99-106. (Pubitemid 43050083)
33. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, Wakefield LM, Letterio JJ, Wynn TA. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-b independent. Journal of Immunology 2004, 173, 4020-4029. (Pubitemid 39280766)
34. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-b in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. Journal of Molecular and Cellular Cardiology 2000, 32, 1805-1819.
35. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, Nagae T, Yahata K, Fujinaga Y, Tanaka I, Nakao K. Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta: a potential target for preventing renal fibrosis. American Journal of Kidney Diseases 2001, 38, S134-S138. (Pubitemid 32927628)
36. Colwell AS, Phan TT, Kong W, Longaker MT, Lorenz PH. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-b stimulation. Plastic and Reconstructive Surgery 2005, 116, 1387-1390; discussion 1391-1392. (Pubitemid 41456511)
37. Zhao Q, ChenN,Wang W-M, Lu J,Dai B-B. Effectof transforming growth factor-beta on activity of connective tissue growth factor gene promoter in mouse NIH/3T3 fibroblasts. Acta Pharmacologica Sinica 2004, 25, 485-489. (Pubitemid 38470420)
38. Li MO, Wan YY, Sanjabi S, Robertson A-K, Flavell L, RA Transforming growth factor-b regulation of immune responses. Annual Reviews of Immunology 2006, 24, 99-146.
39. Pringle GA, Dodd CM. Immunoelectron microscopic localization of the core protein of decorin near the d and e bands of tendon collagen fibrils by use of monoclonal antibodies. Journal of Histochemistry and Cytochemistry 1990, 38, 1405-1411. (Pubitemid 20311130)
40. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. Journal of Cell Biology 1997, 136, 729-743. (Pubitemid 27083772)
41. Weston BS, Wahab NA, Mason RM. CTGF mediates TGF-b-induced fibronectin matrix deposition by upregulating active a5b1 integrin in human mesangial cells. Journal of the American Society of Nephrology 2003, 14, 601-610. (Pubitemid 36246003)
42. Yung S, Lee CY, Zhang Q, Lau SK, Tsang RC, Chan TM. Elevated glucose induction of thrombospondin-1 upregulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF-beta1 dependent and TGF-beta1 independent pathways. Nephrology Dialysis Transplantation 2006, 21, 1504-1513. (Pubitemid 44063124)
43. ShahM,Foreman DM, Ferguson MW. Controlofscarring inadult woundsby neutralising antibody to transforming growth factor beta. Lancet 1992, 339, 213-214.
44. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-b1,2 reduces cutaneous scarring in adult rodents. Journal of Cell Science 1994, 107, 1137-1157.
45. Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis and Rheumatism 2004, 50, 4008-4021. (Pubitemid 39643950)
46. Kusaba A, Fischer 3rd CR, Matulewski TJ, Matsumoto T. Experimental study of the influence of porosity on development of neointima in Gore-Tex grafts: a method to increase long-term patency rate. American Surgeon 1981, 47, 347-354. (Pubitemid 11040356)
47. Watanabe T. Experimental study on the influence of porosity on the development of the neointima in E-PTFE grafts. Nippon Geka Gakkai Zasshi 1984, 85, 580-591.
48. Andrade SP, Fan TP, Lewis GP. Quantitative in-vivo studies on angiogenesis in a rat sponge model. British Journal of Experimental Pathology 1987, 68, 755-766. (Pubitemid 18070320)
49. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membranes directed by membrane microarchitecture. Journal of Biomedical Materials Research 1995, 29, 1517-1524.
50. Updike SJ, Shults MC, Gilligan BJ, Rhodes RK. A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care 2000, 23, 208-214. (Pubitemid 30071026)
51. Ward WK, Slobodzian EP, Tiekotter KL, Wood MD. The effect of microgeometry, implant thickness and polyurethane chemistry on the foreign body response to subcutaneous implants. Biomaterials 2002, 23, 4185-4192. (Pubitemid 34814987)
52. Ward WK, Quinn MJ, Wood MD, Tiekotter KL, Pidikiti S,Gallagher JA. Vascularizing the tissuesurroundingamodelbiosensor: howlocalizedistheeffectofasubcutaneousinfusionof vascularendothelialgrowthfactor(VEGF)?Biosensors&Bioelectronics2003,19, 155-163.
53. Ward WK, Wood MD, Casey HM, Quinn MJ, Federiuk IF. The effectoflocal subcutaneous delivery of vascular endothelial growth factor on the function of a chronically-implanted amperometric glucose sensor. Diabetes Technology & Therapeutics 2004, 6, 137-145. (Pubitemid 38445739)
54. Voskerician G, Gingras PH, Anderson JM. Macroporous condensed poly (tetrafluoroethylene). I. In vivo inflammatory response and healing characteristics. Journal of Biomedical Materials Research A 2006, 76, 234-242.
55. Sanders JE, Stiles CE, Hayes CL. Tissue response to single-polymer fibers of varying diameters: evaluation of fibrous encapsulation and macrophage density. Journal of Biomedical Materials Research 2000, 52, 231-237. (Pubitemid 30491001)
56. Gross KA, Ezerietis E. Juniper wood as a possible implant material. Journal of Biomedical Materials Research A 2003, 64, 672-683. (Pubitemid 37517302)
57. Aho AJ, Rekola J, Matinlinna J, Gunn J, Tirri T, Viitaniemi P, Vallittu P. Natural composite of wood as replacement material for ostechondral bone defects. Journal of Biomedical Materials Research B 2007, 83, 64-71. (Pubitemid 47463197)
58. Smith HR. Do silicone breast implants cause autoimmune rheumatic diseases? Journal of Biomaterials Science, Polymer Edition 1995, 7, 115-121.
59. Godin MS, Waldman SR, Johnson Jr CM. The use of expanded polytetrafluoroethylene (Gore-Tex) in rhinoplasty. A 6-year experience. Archives of Otolaryngology Head and Neck Surgery 1995, 121, 1131-1136.
60. Hurst BS. Permanent implantation of expanded polytetrafluoroethylene is safe for pelvic surgery. United States Expanded Polytetrafluoroethylene Reproductive Surgery Study Group. Human Reproduction 1999, 14, 925-927. (Pubitemid 29176467)
61. Midasch O, Drexler H, Hart N, Beckmann MW, Angerer J. Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. International Archives of Occupational and Environmental Health 2007, 80, 643-648. (Pubitemid 46722213)
62. Wolf CJ, Fenton SE, Schmid JE, Calafat AM, Kuklenyik Z, Bryant XA, Thibodeaux J, Das KP, White SS, Lau CS, Abbott BD. Developmental toxicityof perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicological Sciences 2007, 95, 462-473. (Pubitemid 46152619)
63. http://www.epa.gov/opptintr/pfoa/pubs/pfoainfo.htm#concerns (accessed on August 19 2007).
64. Christenson EM, Anderson JM, Hiltner A. Antioxidant inhibition of poly(carbonate urethane) in vivo biodegradation. Journal of Biomedical Materials Research A 2006, 76, 480-490.
65. Mathur AB, Collier TO, Kao WJ, Wiggins M, Schubert MA, Hiltner A, Anderson JM. In vivo biocompatibility and biostability of modified polyurethanes. Journal of Biomedical Materials Research 1997, 36, 246-257. (Pubitemid 27330048)
66. Wiggins MJ, MacEwan M, Anderson JM, Hiltner A. Effect of soft-segment chemistry on polyurethane biostability during in vitro fatigue loading. Journal of Biomedical Materials Research A 2004, 68, 668-683. (Pubitemid 38263932)
67. Ernsting MJ, Labow RS, Santerre JP. Surface modification of a polycarbonate-urethane using a vitamin-E-derivatized fluoroalkyl surface modifier. Journal of Biomaterials Science, Polymer Edition 2003, 14, 1411-1426. (Pubitemid 38028753)
68. Jahangir AR, McClung WG, Cornelius RM, McCloskey CB, Brash JL, Santerre JP. Fluorinated surface-modifying macromolecules: modulating adhesive protein and platelet interactions on a polyether-urethane. Journal of Biomedical Materials Research 2002, 60, 135-147. (Pubitemid 34126995)
69. Sanders JE, Lamont SE, Karchin A,Golledge SL, Ratner BD. Fibro-porous meshes made from polyurethane micro-fibers: effects of surface charge on tissue response. Biomaterials 2005, 26, 813-818. (Pubitemid 39179965)
70. Koike M, Lockwood PE, Wataha JC, Okabe T. Initial cytotoxicity of novel titanium alloys. Journal of Biomedical Materials Research B 2007, 83, 327-331. (Pubitemid 350010792)
71. Oh K-T, Kang D-K, Choi G-S, Kim K-N. Cytocompatibility and electrochemical properties of Ti-Au alloys for biomedical applications. Journal of Biomedical Materials Research B 2007, 83, 320-326. (Pubitemid 350005000)
72. Assis SL, Rogero SO, Antunes RA, Padilha AF, Costa I. A comparative study of the in vitro corrosion behavior and cytotoxicity of a superferritic stainless steel, a Ti-13Nb-13Zr alloy, and an austenitic stainless steel in Hank's solution. Journal of Biomedical Materials Research B 2005, 73, 109-116. (Pubitemid 40478266)
73. Dinnes DL, Marcal H, Mahler SM, Santerre JP, Labow RS. Material surfaces affect the protein expression patterns of human macrophages: a proteomics approach. Journal of Biomedical Materials Research A 2007, 80, 895-908.
74. Jasty MC, Bragdon C, Burke D, O'Connor D, Lowenstein J, Harris WH. In vivo skeletal responses to porous-surfaced implants subjected to small induced motions. Journal of Bone and Joint Surgery 1997, 79, 707-714. (Pubitemid 27215405)
75. Ward WK, Troupe JE. Assessment of chronically implanted subcutaneous glucose sensors in dogs: the effect of surrounding fluid masses. American Society for Artificial Internal Organs 1999, 45, 555-561. (Pubitemid 30017346)
76. ShenM,PanYV, Wagner MS, Hauch KD, Castner DG, Ratner BD, Horbett TA. Inhibition of monocyte adhesion and fibrinogen adsorption on glow discharge plasma deposited tetraethylene glycol dimethyl ether. Journal of Biomaterials Science, Polymer Edition 2001, 12, 961-978. (Pubitemid 34041515)
77. Cao L, Sukavaneshvar S, Ratner BD, Horbett TA. Glow discharge plasma treatment of polyethylene tubing with tetraglyme results in ultralow fibrinogen adsorption and greatly reduced platelet adhesion. Journal of Biomedical Materials Research A 2006, 79, 788-803. (Pubitemid 44915900)
78. Brodbeck WG, Nakayama Y, Matsuda T, Colton E, Ziats NP, Anderson JM. Biomaterial surface chemistry dictates adherent monocyte/macrophage cytokine expression in vitro. Cytokine 2002, 18, 311-319. (Pubitemid 35007478)
79. Goreish HH, Lewis AL, Rose S, Lloyd AW. The effect of phosphorylcholine-coated materials on the inflammatory response and fibrous capsule formation: in vitro and in vivo observations. Journal of Biomedical Materials Research A 2004, 68, 1-9. (Pubitemid 38030178)
80. Kim K, Kim C, Byun Y. Biostability and biocompatibility of a surface-grafted phospholipid monolayer on a solid substrate. Biomaterials 2004, 25, 33-41. (Pubitemid 37324398)
81. Moro T, Takatori Y, Ishihara K, Konno T, Takigawa Y, Matsushita T, Chung U-I, Nakamura K, Kawaguchi H. Surface grafting of artificial joints with a biocompatible polymer for preventing periprosthetic osteolysis. Nature Materials 2004, 3, 829-836.
82. Moro T, Takatori Y, Ishihara K, Nakamura K, Kawaguchi H. Frank Stinchfield Award: grafting of biocompatible polymer for longevity of artificial hip joints. Clinical Orthopaedics and Related Research 2006, 453, 58-63. (Pubitemid 44900960)
83. Iwasaki Y, Ishihara K. Phosphorylcholine-containing polymers for biomedical applications. Analytical and Bioanalytical Chemistry 2005, 381, 534-546. (Pubitemid 40379326)
84. Geelhood SJ, Horbett TA, Ward WK, Wood MD, Quinn MJ. Passivating protein coatings for implantable glucose sensors: evaluation of protein retention. Journal of Biomedical Research Part B 2006, 81, 251-260. (Pubitemid 46493637)
85. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999, 397, 710-713.
86. Nagata K. Expression and function of heat shock protein 47: a collagen-specific molecular chaperone in the endoplasmic reticulum. Matrix Biology 1998, 16, 379-386. (Pubitemid 28069864)
87. Chen JJ, Zhao S, Cen Y, Liu X-X, Yu R, Wu D-M. Effect of heat shock protein 47 on collagen accumulation in keloid fibroblast cells. British Journal of Dermatology 2007, 156, 1188-1195. (Pubitemid 47029833)
88. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell SR. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. Journal of Biochemistry 1994, 116, 892-897. (Pubitemid 24323674)
89. Kim I, Mogford JE, Witschi C, Nafissi M, Mustoe TA. Inhibition of prolyl 4-hydroxylase reduces scar hypertrophy in a rabbit model of cutaneous scarring. Wound Repair and Regeneration 2003, 11, 368-372. (Pubitemid 37122569)
90. Saika S, Ooshima A, Hashizume N, Yamanaka O, Tanaka S, Okada Y, Kobata S. Effect of lysyl hydroxylase inhibitor, minoxidil, on ultrastructure and behavior of cultured rabbit subconjunctival fibroblasts. Graefe's Archive for Clinical Experimental Ophthalmology 1995, 233, 347-353.
91. Czuwara-Ladykowska J, Makiela B, Smith EA, Trojanowska M, Rudnicka L. The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis. Arthritis Research 2001, 3, 311-318. (Pubitemid 32821525)
92. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Experimental Dermatology 1997, 6, 199-213. (Pubitemid 27421661)
93. Pins GD, Collins-Pavao ME, VanDe Water L, Yarmush ML, Morgan JR. Plasmin triggers rapid contraction and degradation of fibroblast-populated collagen lattices. Journal of Investigative Dermatology 2000, 114, 647-653. (Pubitemid 30226995)
94. Ulrich D, Hrynyschyn K, Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Plastic and Reconstructive Surgery 2003, 112, 1279-1286. (Pubitemid 43933913)
95. Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjostrand SE, Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase. Nature 1981, 290, 159-161. (Pubitemid 11149696)
96. Spector R, Vesell ES. The power of pharmacological sciences: the example of proton pump inhibitors. Pharmacology 2006, 76, 148-155; discussion 156. (Pubitemid 43289468)
97. Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 2002, 23, 1649-1656. (Pubitemid 34158587)
98. Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. Journal of Biomedical Materials Research 2002, 61, 180-187. (Pubitemid 34602364)
99. Anzano MA, Roberts AB, Meyers CA, Komoriya A, Lamb LC, Smith JM, Sporn MB. Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Research 1982, 42, 4776-4778. (Pubitemid 13205989)
100. Katou F, Ohtani H, Nagura H, Motegi K. Procollagen-positive fibroblasts predominantly express fibrogenic growth factors and their receptors in human encapsulation process against foreign body. Journal of Pathology 1998, 186, 201-208. (Pubitemid 28467831)
101. Hernandez-Pando R, Bornstein QL, Leon DA, Orozco EH, Madrigal VK, Cordero EM. Inflammatory cytokine production by immunological and foreign body multinucleated giant cells. Immunology 2000, 100, 352-358. (Pubitemid 30449949)
102. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-b1 and TGF-b2 or exogenous addition of TGF-b3 to cutaneous rat wounds reduces scarring. Journal of Cell Science 1995, 108, 985-1002.
103. Okadome T, Oeda E, Saitoh M, Ichijo H, Moses HL, Miyazono K, Kawabata M. Characterization of the interaction of FKBP12 with the transforming growth factor-b type I receptor in vivo. Journal of Biological Chemistry 1996, 271, 21687-21690. (Pubitemid 26303779)
104. Young GD, Murphy-Ullrich JE. Molecular interactions that confer latency to transforming growth factor-beta. Journal of Biological Chemistry 2004, 279, 38032-38039. (Pubitemid 39195519)
105. Ribeiro SM, PoczatekM,Schultz-CherryS,VillainM,Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-b. Journal of Biological Chemistry 1999, 274, 13586-13593.
106. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expressionbymonocyte chemoattractant protein-1 via specific receptors. Journal of Biological Chemistry 1996, 271, 17779-17784. (Pubitemid 26250752)
107. Duncan MR, Frazier KS, AbramsonS,Williams S,KlapperH,HuangX,Grotendorst GR. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. Journal of the Federation of American Societies for Experimental Biology 1999, 13, 1774-1486.
108. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney International 2002, 62, 1149-1159.
109. Gretzer C, Emanuelsson L, Liljensten E, Thomsen P. The inflammatory cell influx and cytokines changes during transition from acute inflammation to fibrous repair around implanted materials. Journal of Biomaterials Science, Polymer Edition 2006, 17, 669-687. (Pubitemid 44069701)
110. Unemori EN, Beck LS, Lee WP,XuY,SiegelM,KellerG,Liggitt HD, Bauer EA, Amento EP. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. Journal of Investigative Dermatology 1993, 101, 280-285. (Pubitemid 23269897)
111. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJP, Unemori EN, Iredale JP. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001, 49, 577-583. (Pubitemid 32896990)
112. Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. Journal of Investigative Dermatology 1990, 95, 75S-80S.
113. Fais S, Burgio VL, Silvestri M, Capobianchi MR, Pacchiarotti A, Pallone F. Multinucleated giant cells generation induced by interferon-gamma. Changes in the expression and distribution of the intercellular adhesion molecule-1 during macrophages fusion and multinucleated giant cell formation. Laboratory Investigation 1994, 71, 737-744. (Pubitemid 24374581)
114. Khouw IM, van Wachem PB, De Leij LFMH, Van Luyn MJA. Inhibition of the tissue reaction to a biodegradable biomaterial by monoclonal antibodies to IFN-gamma. Journal of Biomedical Materials Research 1998, 41, 202-210. (Pubitemid 28272477)
115. Miles RH, Paxton TP, Zacheis D, Dries DJ, Gamelli RL. Systemic administration of interferon-gammaimpairswoundhealing.JournalofSurgicalResearch 1994,56,288-294.
116. Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, Muller GA. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrology Dialysis Transplantation 2000, 15, 1535-1546.
117. Higashi K, Inagaki Y, Fujimori K, Nakao A, Kaneko H, Nakatsuka I. Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3. Journal of Biological Chemistry 2003, 278, 43470-43479. (Pubitemid 37345970)
118. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine 1993, 329, 1456-1162.
119. Perico N, Ruggenenti P, Remuzzi G. Losartan in diabetic nephropathy. Expert Review of Cardiovascular Therapy 2004, 2, 473-483. (Pubitemid 39069784)
120. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. American Journal of Kidney Diseases 1999, 34, 818-823. (Pubitemid 29521696)
121. Abiko M, Rodgers KE, Campeau JD, Nakamura RM, Dizerega GS. Alterations of angiotensin II receptor levels in full-thickness excisional wounds in rat skin. Wound Repair and Regeneration 1996, 4, 363-367. (Pubitemid 126670853)
122. Sun Y, Weber KT. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. Journal of Laboratory and Clinical Medicine 1996, 127, 94-101. (Pubitemid 126690992)
123. Gilligan BJ, Shults MC, Rhodes RK, Updike SJ. Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model. Diabetes Care 1994, 17, 882-887. (Pubitemid 24235512)
124. Klueh U, Dorsky DI, Kreutzer DL. Use of vascular endothelial cell growth factor gene transfer to enhance implantable sensor function in vivo. Journal of Biomedical Materials Research A 2003, 67, 1072-1086. (Pubitemid 37522719)
125. Klueh U, Dorsky DI, Kreutzer DL. Enhancement of implantable glucose sensor function in vivo using gene transfer-induced neovascularization. Biomaterials 2005, 26, 1155-1163. (Pubitemid 39286825)
126. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006, 26, 275-278. (Pubitemid 44318179)